An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia
Latest Information Update: 26 Dec 2025
At a glance
- Drugs Bleximenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 26 Dec 2025 New trial record